Tech Company Financing Transactions
ADARx Pharmaceuticals Funding Round
Ascenta Capital, Lilly Asia Ventures and OrbiMed joined a $46 million Series B venture round for ADARx Pharmaceuticals. The round was announced on 1/20/2023.
Transaction Overview
Company Name
Announced On
1/20/2023
Transaction Type
Venture Equity
Amount
$46,000,000
Round
Series B
Investors
Ascenta Capital (Lead Investor) (Lorence Kim)
Proceeds Purpose
The company intends to use the funds to advance its proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5871 Oberlin Dr. 200
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
ADAR is an acronym for Adenosine Deaminase Acting on RNA. As such, our name may make you think of RNA editing, but that's only part of the story. The word adar means wide or great which aptly describes the opportunities for our RNA targeting platform.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Zhen Li
Vice President
Melissa Fisher
Vice President
Timothy Young
VP - R & D
Rui Zhu
Browse more venture capital transactions:
Prev: 1/20/2023: Akia venture capital transaction
Next: 1/21/2023: Nourish venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to document every notable VC transaction. All VC database entries reported here come from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs